Third Quarter 2022 Results
Bayer AG Media Conference Call
Bayer with Continued Strong Performance
- Group sales increase by 5.7 percent (Fx & portfolio adj.) to 11.281 billion euros
- EBITDA before special items rises by 17.3 percent to 2.451 billion euros
- Crop Science achieves strong sales gains – sales also up at Pharmaceuticals and Consumer Health
- All divisions report significant increase in earnings
- Core earnings per share climb by 7.6 percent to 1.13 euros
- Net income at 546 million euros
- Free cash flow at 1.738 billion euros
- Major progress in Pharmaceuticals pipeline
- Full-year Group outlook confirmed
Links:
Statement in written form and presentation slides
Audio Recording (dubbed into English):
Speakers
